BTK Inhibitors Versus Venetoclax as First- or Second-Line Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Evidence Study

被引：0
|
作者：
Roeker, Lindsey E. [1 ]
Han, Yi [2 ]
Teschemaker, Anna [3 ]
Mato, Anthony R. [1 ]
Thompson, Meghan C. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA
[2] Vinzent Strategies, Blue Bell, PA USA
[3] AstraZeneca, Gaithersburg, MD USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2025年 / 100卷 / 04期
关键词：
Bruton tyrosine kinase inhibitor; chronic lymphocytic leukemia; real-world evidence; small lymphocytic lymphoma; venetoclax;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：720 / 723
页数：4
相关论文
共 50 条
  • [31] BTK Inhibitor Ibrutinib/Zanubrutinib Plus Bendamustine and Rituximab As the Initial Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia : a Single Arm Real-World Study
    Zhu, Huayuan
    Wu, Wei
    Sha, Yeqin
    Jin, Ze
    Yang, Yilian
    Qiu, Jingyan
    Ding, Chongyang
    Wang, Zhen
    Shi, Chuanbing
    Peng, Chen
    Mi, Hongling
    Chen, Ruize
    Wang, Li
    Fan, Lei
    Xu, Wei
    Li, Jianyong
    BLOOD, 2021, 138
  • [32] Italian Real-World Analysis of a Tyrosine Kinase Inhibitor Administration as First- or Second-Line of Therapy in Patients with Chronic Myeloid Leukemia
    Perrone, Valentina
    Giacomini, Elisa
    Andretta, Margherita
    Arenare, Loredana
    Cillo, Maria Rosaria
    Latini, Marisa
    Mecozzi, Alessandra
    Pagliaro, Romina
    Vercellone, Adriano
    Degli Esposti, Luca
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2021, 17 : 617 - 622
  • [33] Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Ammann, Eric M.
    Shanafelt, Tait D.
    Larson, Melissa C.
    Wright, Kara B.
    McDowell, Bradley D.
    Link, Brian K.
    Chrischilles, Elizabeth A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (12): : E11 - E25
  • [34] Real-world treatment patterns in first line and relapsed Chronic Lymphocytic Leukemia (CLL)
    Feinberg, Bruce
    Schenkel, Brad
    McBride, Ali
    Ellis, Lorie
    Radtchenko, Janna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S204 - S205
  • [35] Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
    Blomstrand, Hakon
    Batra, Atul
    Cheung, Winson Y.
    Elander, Nils Oskar
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (09): : 787 - 799
  • [36] Real-World Evaluation of Treatment Discontinuation and Healthcare Resource Utilization in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Chanan-Khan, Asher Alban
    Challagulla, Swetha
    Donckels, Elizabeth
    Chuang, Po-Ya
    Yang, Keri
    BLOOD, 2023, 142
  • [37] REAL-WORLD ECONOMIC OUTCOMES OF FIRST-LINE (1L) IBRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
    Challagulla, S.
    Lee, P.
    Kistler, K.
    Douyon, L.
    Lai, D.
    Iyengar, R.
    VALUE IN HEALTH, 2021, 24 : S38 - S38
  • [38] Kinetics of Lymphocytosis during First- Line Treatment with BTK Covalent Inhibitors in Chronic Lymphocytic Leukemia Patients: An Italian Multicenter Experience of Real Life
    Innocenti, Idanna
    Mosca, Antonio
    Tomasso, Annamaria
    Galitzia, Andrea
    Scarfo, Lydia
    Galli, Eugenio
    Laureana, Roberta
    Benintende, Giulia
    Mattiello, Veronica
    Morelli, Francesca
    Chiriu, Sabrina
    Del Principe, Maria Ilaria
    Frustaci, Annamaria
    Zamprogna, Giulia
    Gentile, Massimo
    Fabbri, Nicole
    Autore, Francesco
    Montalbano, Maria Chiara
    Farina, Giuliana
    Innao, Vanessa
    Patti, Caterina
    Sportoletti, Paolo
    Fresa, Alberto
    Catania, Gioacchino
    Coscia, Marta
    Tedeschi, Alessandra
    Sanna, Alessandro
    Visentin, Andrea
    Trentin, Livio
    Varettoni, Marzia
    Ghia, Paolo
    Murru, Roberta
    Laurenti, Luca
    BLOOD, 2023, 142
  • [39] Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax plus Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors
    Ravelo, Arliene
    Patel, Achal
    To, Tu My
    Li, Sophia S.
    Huntington, Scott
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S345 - S345
  • [40] FIRST LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA IN THE ERA OF NEW MOLECULES
    Vazquez Diaz, M. S.
    Paumard Rodriguez, E.
    Martin Palanco, V
    Fernandez de la Mata, M.
    HAEMATOLOGICA, 2019, 104 : 284 - 285
12345